Medical and Chemical TOC Members

I, Emmanuel Addo-Yobo, nominated by UNEP Ozone Secretariat, residing in Ghana, and a member of the Medical and Chemicals Technical Options Committee declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Professor in the Department of Child Health, Kwame Nkrumah University of Science and Technology, and Honorary Consultant Paediatrician with sub-specialty interest in paediatric pulmonology in the Directorate of Child Health, Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana. My responsibilities include general paediatric clinical care, clinical teaching and mentoring of undergraduate and postgraduate medical students. I am the clinical consultant-in-charge of Paediatric Asthma Clinic KATH. I have been involved in many research activities on childhood asthma epidemiology in Ghana as Principal or Co-Investigator, some of which have been sponsored partly or fully by pharmaceutical companies.  I do not receive any form of remuneration from any drug companies. I have, however, given educational lectures to medical personnel on childhood asthma in Ghana which were sponsored by drug companies in a purely academic capacity.  
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following:
   1. Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: 
      My business has an interest in the topics of the Montreal Protocol with regard to my patients with asthma and COPD who may be using MDIs containing ODS where there are no other affordable and effective alternatives.  My spouse is a business secretary working with a local financial institution in Ghana and has no interests in matters before the Protocol.
   4. Government advice and other policy development: I served as a member of the National Expert Committee for the review of Standard Treatment Guidelines for Ghana (2016-2017). My role in this Committee included advising prescribers on safe and cost-effective treatments for asthma and COPD, and other disorders in my capacity as a clinician. I am also currently the chair of the National Poliomyelitis Expert Commitee (NPEC).
   5. Paid research activities, fellowships or grants: I am not involved in any paid research activities, fellowships or grants relevant to the MCTOC activity.  
   6. Other interests: None
5. The source of funding for my participation in the work of the Medical Technical Options Committee has been the Ozone Secretariat of the United Nations Environmental Programme (UNEP). 
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:  Professor Emmanuel Addo-Yobo  
Date: 29th April 2020
 

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Fatima Al-Shatti, nominated by Kuwait, residing in Kuwait, a (member/co-chair) of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
   I am (Environment Advisor with Kuwait Environment Public Authority. I am responsible for environment.). My responsibilities include (describe current work interests/areas of focus).
2. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
3. My interests ¹, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. employment, consultancy, directorship or other positions: Except for my part time work with  Kuwait EPA as consultant, neither I nor my family are employed by, do not consult for, and do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.
   4. Government advice and other policy development: None 
   5. Paid research activities, fellowships or grants: No conflicts  
   6. Other interests: No conflicts   
4. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is, UNEP’s Ozone Secretariat 
5. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have no declined to disclose information falling within paragraph 10 of those Guidelines. 
6. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
7. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
8. I understand that this DOI will expire no later than one year after I have signed it.

Name: Fatima Al-Shatti
Date: 30th April 2020                                                      
 

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Paul J. Atkins, nominated by the United States of America and residing in the United States, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I recently retired as Vice President at Oriel Therapeutics Inc (a Novartis company) where my responsibilities included general management and technical input into programs focused on the development and manufacture of inhaled medicines.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner, include the following - 
   1. Proprietary interests: None
   2. Financial interests: Shares in Novartis and my spouse owns shares in her employer (GSK a manufacturer of inhaled medicines)
   3. Employment, consultancy, directorship or other positions:  No current consulting interests
   4. Government advice and other policy development: None
5. Paid research activities, fellowships or grants: None
6. Other interests: N/A
7. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my personal funds
8. Pursuant to paragraph 11 of the COI Guidelines I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussions and decisions on topics related to the information that I have declined to disclose.
9. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
10. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
11. I understand that this DOI will expire no later than one year after I have signed it.

Paul J. Atkins PhD.
16th June 2020

I, William Auriemma, nominated by and residing in the United States of America, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I serve as Chief Executive Officer of Diversified CPC International, Inc. engaged in the supply of aerosol propellants to the consumer products industry. We do extensive work in determining commercial viability of “next generation” propellant systems. My role as Past Chairman of the Household & Commercial Products Association allows for direct interaction with U.S. regulatory agencies.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following:
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies.
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   3. Employment, consultancy, directorship or other positions: My company works closely with major U.S. based manufacturers of low GWP substances and is the marketing and distribution arm of these products to the aerosol and medical device industries.
   4. Government advice and other policy development: See above under item c.
   5. Paid research activities, fellowships or grants: None.
   6. Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is our company, Diversified CPC International, Inc. and they will bear all related costs. There are no consulting fees involved.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:  William Auriemma
Date:    May 4, 2020

I, Dr. Christian SEKOMO BIRAME, nominated by Rwanda Environmental Management Authority (REMA) / RWANDA, residing in RWANDA, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Senior Lecturer at the University of Rwanda (UR) in the College of Science and Technology (CST) / School of Science (SoS) / Department of Chemistry. I use to teach the following modules:  Analytical Chemistry I & II; Environmental Chemistry I, Fundamental of waste management at undergraduate level and Water Quality Principles and Management; Wastewater Treatment and Disposal; Supervision of laboratory work and BSc final year project as well as MSC and PhD thesis. Beside my daily university workload I use to conduct many consultancies work for the Ministry of Environment and REMA mainly related with waste management in general (water quality analysis; Hazardous chemical waste management (POPs, PCBs and Hg). Recently I have worked with a team of IT specialist in the development of an IT system for ODS management in Rwanda for REMA.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following: 
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.  
   3. Employment, consultancy, directorship or other positions: I have an interest to conduct consultancy services in the topics of the Montreal Protocol because my potential client is also interested in these topics. I consult for an organisation that supports the Montreal Protocol in phasing out controlled substances.
   4. Government advice and other policy development: See above under c.
   5. Paid research activities, fellowships or grants: None
   6. Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee will be provided by the Ozone Secretariat to support travel and accommodation when I will be attending MCTOC planned meetings.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Dr. Christian SEKOMO BIRAME
Date: 30th April 2020
 

I, Olga Blinova, nominated by the Russian Federation, residing in the Russian Federation, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a full-time, salaried employee at Russian Scientific Center “Applied Chemistry”, based in the Russian Federation, which develop manufacture processes for fluorinated substances. I work for the company as Leading Researcher of Fluorine Chemistry Department. My responsibilities include investigation in the area of fluorine chemistry.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: No.
   4. Government advice and other policy development: No. 
   5. Paid research activities, fellowships or grants: No.
   6. Other interests: 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP, Ozone Secreteriate.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Olga Blinova 
Date: April 15, 2020 
 

I, Steve Burns, nominated by and residing in UK, a member of the Medical and Chemicals Technical Options Committee, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am VP Project Leadership at AstraZeneca Plc. My responsibilities include strategy, planning and execution of AstraZeneca’s pharmaceutical development projects (including provision of technical support to on market brands)
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
   My interests, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces) except via the share awards issued to me under the AstraZeneca Long Term Incentive plan (see financial interests below)
   2. Financial interests: I have been awarded shares as part of the AstraZeneca Plc Long Term Incentive scheme. These shares vest and become available to me following a vesting period of three years subject to performance criteria being met. The performance criteria include financial performance which is in part linked to the sale of products containing HFA propellants.
   3. I am employed by AstraZeneca which offers for sale dry powder inhalers, nebulisers and pressurised metered dose inhalers containing HFc propellants.
4. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is AstraZeneca
5. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
6. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
7. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
8. I understand that this DOI will expire no later than one year after I have signed it.

Name: Steve Burns
Date: 13rd May 2020

1. I, Nicholas J. Campbell nominated by France, member of the Medical and Chemicals Technical Options Committee and CFC-11 TEAP Task Force, declare as follows:
2. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
3. I work for ARKEMA SA, based in Paris, as the Environment Manager for the Fluorinated Products Division.
4. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
5. My interests include the following –
   1. Proprietary interests: I do not have a proprietary interest in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies.
   2. Financial interests: I have stock options in ARKEMA SA. ARKEMA SA is a producer of HCFCs, HFCs and HFOs.
   3. Employment, consultancy, directorship or other positions: I am Chairman of the European Fluorocarbon Technical Committee (EFCTC) that represents the producers of fluorocarbons in the European Union. I am also a member of the World Bank’s Ozone Operations Resource Group.
   4. Government advice and other policy development: I do not provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   5. Paid research activities, fellowships or grants: I do not receive any paid research activities or any fellowships or grants for work related to a proposed use of an ozone-depleting substance, a hydrofluorocarcarbon or an alternative to a proposed use of an ozone depleting substance.
   6. Other interests: I do not have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.
6. ARKEMA SA supports my participation and travel on MCTOC and the CFC-11 TEAP Task Force.
7. Pursuant to paragraph 11 of the COI Guidelines I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
8. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
9. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee and the CFC-11 TEAP Task Force.
10. I understand that this DOI will expire no later than one year after I have signed it.

Signed: Nicholas J. Campbell (signed electronically by submission)
Date: 15th April, 2020
 

I, Richard J, Cooke, nominated by Canada, residing in Canada, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am President and Principle Consultant at Man-West Environmental Group Ltd., a company engaged in environmental consulting. My responsibilities include acting as an independent consultant directing and supporting work in the areas of related to waste management, contaminated sites management, and the demonstration of technologies for chemicals destruction under requirements applied by the Stockholm Convention on Persistent Organic Pollutants, and the Montreal Protocol.  Principle clients include Implementing Agencies for the GEF and MLF. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following: 
   1. Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: Current or potentially active assignments in 2020 possibly relevant to the MCTOC are: MLF/GEF End of Life ODS/HFC Destruction Demonstration in projects, GEF POPs Elimination Projects in Turkey and Belarus, Arctic Council POPs Destruction Demonstrations in Russia; and a study assignment for UNDP related to development of funding mechanisms for ODS and HFC destruction (declared in advance to MTOC chair). 
   4. Government advice and other policy development: The above projects involve provision of advice on policy issues and program implementation to the respective governments that may be relevant to the MCTOC activity.
   5. Paid research activities, fellowships or grants: None
   6. Other interests: Protection of Rocky Mountain wildlife habitat connectivity, particularly large carnivores. 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Man-West Environmental Ltd. in which I am the principle shareholder, making my participation effectively self-funded. 
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:  Richard J. Cooke
Date:    April 20, 2020
 

I, Maureen George, residing in the United States a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an Associate Professor at Columbia University School of Nursing. My responsibilities include leading an independent program of research in asthma, COPD and ILD in vulnerable populations, teaching in the PhD and master’s nursing programs, and meeting other service requirements.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
   My interests¹, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: Honoraria received for advisory/consultant roles with Astra-Zeneca, Genentech and Mylan Pharmaceuticals.
   4. Government advice and other policy development: None.
   5. Paid research activities, fellowships or grants: None.
   6. Other interests: None. 
4. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Columbia University. By “funding” I mean I will be paid my regular annual salary for the time spent on this committee work and will receive partial reimbursement for committee travel expenses. I will personally cover all other expenses relating to my work on behalf of the committee.
5. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
6. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
7. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
8. I understand that this DOI will expire no later than one year after I have signed it.

Name:  Maureen George

Date: 4/15/20

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Kathleen Hoffman, nominated by United States of America, residing in United States of America, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed by Sotera Health as Sr. Vice President of Global Environmental, Health and Safety. My responsibilities include leading the company’s global environmental, health, safety and security management program across the three difference Sotera business units.  Other responsibilities include oversight of various regulatory actions and participation with various government and trade association groups on regulatory and technical topics.  Sotera is a holding company that leads in the contract sterilization and testing services for the medical device and pharmaceutical industries. We utilize ethylene oxide and radiation for the sterilization and bio reduction of medical products, cosmetics and food products.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: See response to #2.
   4. Government advice and other policy development: See response to #2.
   5. Paid research activities, fellowships or grants:  None
   6. Other interests:  None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is by a voluntary basis.  However, such funding is very limited because my participation is mainly done on a remote basis.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:        Kathleen Hoffman
Date:         May 1, 2020

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Jianxin Hu nominated by China, and residing in China, a Member of the Medical and Chemicals Technical Options Committee and member of the Decision XXXI/3 Task Force on Unexplained Emissions of CFC-11 declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor of Environmental Sciences at Peking University in China. My responsibilities include teaching and researching on environmental management on Chemicals, especially relate to HFCs, ozone-depleting substances, and persistent organically pollutants, as an independent consultant providing strategic, policy and technical advice to government, industry and other non-governmental organizations.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs. 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: See following.
   4. Government advice and other policy development: See following. Paid research activities, fellowships or grants: My research work has an
   5. interest in the topics of the Montreal Protocol, because I work for organisations that support the Montreal Protocol in phasing out ODS. Such as in 2015, I had a project which is drafting Chinese HCFCs Phaseout Plan for the government. This project paid by MLF.
   6. Other interests: 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jianxin Hu
Date: March 14, 2020

I, Ryan Hulse nominated by USA, residing in USA, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Research and Development Director at Honeywell International. My responsibilities include leading the applications team in the development of new products in the areas Aerosol, Solvent, Refrigerants and Foam Blowing Agents. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests , and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). As part of my work at Honeywell I have developed aerosol and solvent alternatives to CFC and HCFCs.  These rights for the patents are wholly owned by Honeywell.
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.  
   3. Employment, consultancy, directorship or other positions: Honeywell has interest in the topics of the Montreal Protocol in that they are developing low global warming potential and non-ozone depletion potential alternatives to current CFC and HCFCs.
   4. Government advice and other policy development: none
   5. Paid research activities, fellowships or grants: none
   6. Other interests: 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is from Honeywell Int.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Ryan Hulse
Date: April 30, 2020

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Rabinder N Kaul, nominated by, and residing in India, appointed as member of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXXI/3 declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I presently work for SRF Limited as a consultant. I am also Secretary of REGMA, an industrial association of refrigerant gases manufacturers in India.  My responsibilities include work related to the Montreal Protocol and related MEAs and the regulatory issues.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do have some shares in an entity with an interest in the subject
   3. Employment, consultancy, directorship or other positions: I am also Secretary of the Refrigerant Gas Manufacturers Association (REGMA)
   4. Government advice and other policy development: Do not provide advice on significant issues to a Government in respect of policy.
   5. Paid research activities, fellowships or grants: I do not receive paid research activities or any fellowships /grants relevant to the TEAP activity.
   6. Other interests: No other interests related to the subject matter of TEAP/Montreal Protocol
5. The source of funding for my participation in the work of the TOC and TEAP’s Task Force on Unexpected emissions of CFC 11. The travel and stay is funded by the Ozone Secretariat as Article 5 participant.   Professional services are however voluntary.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TOC and TEAP Temporary Subsidiary Body.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name:   Rabinder N Kaul
Date:    April 1, 2020
 

I, DR. JAVAID A. KHAN_, nominated by (add party) AGA KHAN UNIVERSITY, KARACHI, residing in (add party) _PAKISTAN_, a (Member/co-chair) of the Medical and Chemicals Technical Options Committee declare as follows. 

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies ("the COI Guidelines") as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am (describe your affiliations, including job title, employing organization). My  responsibilities include (describe current work interests/areas of focus).
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   1. Proprietary interests: I (have/ do not have) proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
   2. Financial interests: I (have/ do not have) ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (add description of interest; relevant financial relationships between members should be disclosed)
   3. Employment, consultancy, directorship or other positions: (describe any interests relevant to the MCTOC activity).
   4. Government advice and other policy development: (describe any interests relevant to the MCTOC activity, including any provision of advice to government, organizations or institutions involved in policy development)
   5. Paid research activities fellowships or grants: (describe any paid research activities, fellowships or grants relevant to the MCTOC activity)
   6. Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is (describe funding arrangements and source2)
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I (have/have not) declined to disclose information falling within paragraph 10 of those Guidelines (if have declined, add the following at the end of this statement "and I undertake to   ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose"). 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: JAVAID A. KHAN

Date: April 28 2020

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Andy Lindley, nominated by United Kingdom, residing in United Kingdom, a member of the Medical and Chemicals Technical Options Committee and the XXXI/3 CFC-11 TEAP Task Force declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am an independent consultant providing services to Koura Global and EFCTC. My responsibilities include the European Fluorocarbon Technical Committee (EFCTC) mainly focused on HFCs and HFOs, their applications and EFCTC website content development and newsletter production. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: None.
   4. Government advice and other policy development: None. 
   5. Paid research activities, fellowships or grants: None.
   6. Other interests: No conflict.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is none as no funding is required for my participation as a corresponding member. ²
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not  declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Andy Lindley
Date: 18 April 2020

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

² Where a Member benefits from finance that has been channelled through a conduit, the Member should also identify the source of the finance.

I, Gerald McDonnell, nominated by United Kingdom, residing in United States, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Senior Director at DePuySynthes, a Johnson & Johnson company. My responsibilities include microbiological quality and sterility assurance.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests , and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have) proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. I am a minor shareholder in Johnson & Johnson, a user of sterilization technology.
   3. Employment, consultancy, directorship or other positions: I am an employee for Johnson & Johnson who uses radiation, heat and gas sterilization procedures for product manufacturing.
   4. Government advice and other policy development: None.
   5. Paid research activities, fellowships or grants: None.
   6. fOther interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Johnson & Johnson.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Dr. Gerald McDonnell
Date: April 16, 2020
 

I, Robert J. Meyer, MD, nominated by The United States of America, residing in the USA, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Principal in Drugs and Biological Products development at Greenleaf Health.  My responsibilities include advising companies on drug/biological development for human disease, specifically focusing on success in engaging with and addressing the US FDA’s expectations for safe and effective drugs.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   2. Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.  I have equity interest in Pfizer, Johnson and Johnson – two large Pharma companies with broad portfolios
   3. Employment, consultancy, directorship or other positions: My work at Greenleaf Health does entail consulting for companies developing inhalation drug products
   4. Government advice and other policy development: None
   5. Paid research activities, fellowships or grants: None
   6. Other interests: 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is personally supported and/or through my employer  
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Robert J. Meyer, MD
Date: 15-Apr-2020
 

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Dr. B. Narsaiah, nominated by the Government of India, residing in India, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Dr. B. Narsaiah, Chief Scientist & Head (retired), Fluoroorganic division, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad – 500007, India. My responsibilities included development of technologies for ozone friendly chemicals and Synthesis of novel fluorinated molecules of biological interest. As I am superannuated from service, I am extending my expertise in Telangana state Environmental Impact Assessment Authority (TSEIAA) committee in giving environmental clearance to various projects like expansion of pharmaceutical industries, mines related to granites, sand, multiplex buildings under specified guidelines. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (Development of technologies for alternatives to ozone depletion chemicals)
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work..
   3. Employment, consultancy, directorship or other positions: I have an interest to extend consultancy services to the proposed activities in TEAP.
   4. Government advice and other policy development: I have an interest to extend consultancy services to the proposed activities in TEAP. 
   5. Paid research activities, fellowships or grants: Based on the options available to extend advisory services, I will coordinate paid research activities. 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is through the Ozone secretariat of the Montreal Protocol, which will fund my participation .
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Dr. B. Narsaiah
Date: April 30, 2020
 

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Timothy James Noakes, nominated by the United Kingdom, residing in the United Kingdom, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed by Koura (a company specialising in fluorinated gases including MDI propellants) as a Technical Associate. My responsibilities include maintaining a global view of the respiratory inhalers market and advancing the technology of MDI propellants and their use.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following:
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   3. Employment, consultancy, directorship or other positions. I am a full – time employee of Koura, a leading global manufacturer of HFC gases including HFC 134a. I have worked for Mexichem (now Koura) for 25 years developing and then supporting the sale of medical grades of this propellant for use in MDIs. My main interest is in technical matters relating to use and performance. I am now involved in developing a new lower carbon MDI propellant HFC 152a.
   4. Government advice and other policy development. No contacts at present.
   5. Paid research activities, fellowships or grants: None.
   6. Other interests: 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my employer.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Timothy James Noakes
Date:   15/4/2020
 

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, John G. Owens, appointed by the Halons Technical Options Committee co-chairs as a Consulting Expert, residing in the United States of America, declare as follows:

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed full-time as a lead research specialist for 3M Company, Saint Paul, Minnesota, USA. 3M Company has an interest in the topic of the Montreal Protocol because it is a manufacturer of technologies which formerly used ozone depleting substances and manufactures alternatives to ODSs.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my spouse include the following – 
   1. Proprietary interests: Neither I nor my spouse, have a proprietary interest in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies.
   2. Financial interests: I own shares of stock in my employer, 3M Company, which is an entity with an interest in the Montreal Protocol as stated above.  Should a conflict arise due to activities related to my employer, I will recuse myself as delineated in Decision XXIV/8
   3. Employment, consultancy, directorship or other positions: Except for my employment at 3M Company, neither I nor my spouse are employed by, do not consult for, do not serve as a director of or hold any other position for any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel.
   4. Government advice and other policy development: Neither I nor my spouse provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   5. Paid research activities, fellowships or grants: Neither I nor my spouse are the recipients of any paid research activities or any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance. 
   6. Other interests: Neither I nor my spouse have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.
5. The source of funding for my participation in the work of the Halons Technical Options Committee, the Technology and Economics Assessment Panel, and the Task Force XXV/5 comes from my employer, the 3M Company.
6. Pursuant to paragraph 11 of the COI Guidelines I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a Consulting Expert to the Halons Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.
    

Signed: John G. Owens
Date: 29 April 2020

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Jose Pon, nominated by Venezuela residing in United States, a Member of the Medical and Chemicals Technical Options Committee and Co-chair of the CFC 11 Task Force declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options  and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am president of Spray Quimica CA and Sicamu Inc. My responsibilities include managing aerosol filling plants.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: None
   4. Government advice and other policy development: None
   5. Paid research activities, fellowships or grants: None
   6. Other interests: 
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Montreal Protocol Secretariat
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jose Pons
Date: 5/05/20
 

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Hans Porre,  nominated by The Netherlands, residing in The Netherlands, a (member/co-chair) of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a full-time, salaried employee at Teijin Aramid B.V., based on Delfzijl, which manufactures aramid polymer (poly-paraphenyleenterephtalamide). I work for the company as environmental coordinator. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: (not applicable).
   4. Government advice and other policy development: (not applicable)
   5. Paid research activities, fellowships or grants: (not applicable)
   6.  Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Teijin Aramid B.V.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: J.G.W. Porre
Date: April 28, 2020

I, John Pritchard, nominated by and residing in United Kingdom, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am now acting as an independent consultant to clients developing respiratory drugs, delivery systems and digital healthcare, trading under the company name of Inspiring Strategies. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following:
   1. Proprietary interests: We do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   2. Financial interests: My wife and I have minority ownership of shares in various pharmaceutical companies who develop, manufacture and sell respiratory products that are impacted by decisions taken under the Montreal Protocol.
   3. Employment, consultancy, directorship or other positions: I consult to a variety of clients, some of whom may be commercially impacted by decisions taken under the Montreal Protocol. In particular, I am a non-Executive Director for Cardiff Scintigraphics, and a Director of iPharma, both contract research organisations providing formulation development and testing of inhaled products.
   4. Government advice and other policy development: None
   5. Paid research activities, fellowships or grants: None
   6. Other interests: None
5. I receive no funding for my participation in the work of the Medical and Chemicals Technical Options Committee. Travel expenses might in the future be supported either by client relationships or the UK Government. 
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: JN Pritchard
Date: 15 Apr 2020
 

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, Rabbur Reza, nominated by Bangladesh (A5), a member of the Medical and Chemical Technical Options Committee, declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh and as Managing Director at Nuvista Pharma Ltd., Bangladesh. As the operational leader I am overseeing both Company’s business operations, which include pharmaceutical formulation and raw material manufacturing & quality control, research & development, regulatory affairs, training (learning & development management), sales, marketing and brand management, distribution, international business development, informational technology, medical affairs, project management, human resources etc.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following: 
   1. Proprietary interests: My employer Beximco Pharmaceuticals is the largest medical inhalers (MDI & DPI) manufacturer in Bangladesh and has an interest in the topics of Montreal Protocol, as it is engaged in development, manufacturing and marketing of MDIs in local and international markets. I have no proprietary interest in alternatives or substitutes to ODS.
   2. Financial interests: I do not own stock in companies producing ODS or alternatives or substitutes to ODS, and do not have an interest in the outcome of essential use nominations.
   3. Employment, consultancy, directorship or other positions: I work as full time Chief Operating Officer at Beximco Pharmaceuticals Ltd, Bangladesh and as Managing Director at Nuvista Pharma Ltd., Bangladesh. I also serve as a director on the board of BioCare Manufacturing Sdn Bhd., Malaysia. BioCare is involved in manufacturing MDIs. My spouse is a medical practitioner and has no interest in matters before the Protocol.
   4. Government advice and other policy development: None.
   5. Paid research activities, fellowships or grants: None.
   6. Other interests: None.
5. UNEP’s Ozone Secretariat funds my travel expenses for participation on MTOC.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Rabbur Reza
Date: 30th April 2020

I, Raj Sharma nominated by MTOC Chair , residing in UK a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Medical Affairs Lead for asthma at GSK My responsibilities include evidence generation and scientific communications 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   2. Financial interests: I have shares or bonds in an entity with an interest in the subject matter of the meeting or work. GSK manufactures metered dose inhalers and dry powder inhalers  
   3. Employment, consultancy, directorship or other positions: I  am employed by GSK
   4. Government advice and other policy development: N/A
   5. Paid research activities :N/A
   6. Other interests: N/A
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is GSK
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Rajiev Sharma
Date: 01 May 2020
 

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, David Sherry, residing in the United Kingdom of Great Britain and Northern Ireland, appointed as member of TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXXI/3, and member of the Medical and Chemicals Technical Options Committee, declare as follows. 

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Co-Director and co-owner of Nolan Sherry and Associates Ltd (NSA). NSA specialises in the chlorine and fluorine chemical industries, providing technical, commercial, strategic and regulatory advice to the chemical industry, trade associations and government organisations. My responsibilities have included studies on HFOs and CTC, chloromethanes, chloroethanes, the commercial outlook for CTC; technical expertise in patent law, due diligence audits of CDM beneficiaries, provision of estimated emission rates for various chlorocarbons to various atmospheric researchers, and various evaluation and monitoring projects for UNMFS, UNDP, and World Bank.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with these Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have any proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. (co-owner of NSA Ltd, as described above)
   3. Employment, consultancy, directorship or other positions: see above.
   4. Government advice and other policy development: see above
   5. Paid research activities, fellowships or grants: none
   6. Other interests: none relevant: 
5. The source of funding for my participation in the work of the TEAP Task Force on destruction technologies is the UK Department of Environment, Food, and Rural Affairs (DEFRA), who fund specific travel and hotel costs with limited DSA. As a self-employed consultant, the time, medical requirements for travel, and cost of my contribution to the CFC-11 Task Force and to MCTOC is self-funded
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have declined to disclose information falling within paragraph 10 of those and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the TEAP Temporary Subsidiary Body.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: David Sherry
Date: 21 April 2020

I, Peter Sleigh, nominated by, and residing in, the United Kingdom, a member of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexpected Emissions of CFC-11 under Decision XXX/3 declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am employed as a Regulatory Manager for Koura, a producer and distributor of fluorinated products. My responsibilities include ensuring regulatory compliance particularly in Europe.  Koura has an interest in the topics of the Montreal Protocol because they sell fluorochemicals controlled by the protocol.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following (if answer is yes, describe briefly)
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: On behalf of Koura I am Chairman of GlobalFACT an industry association for global fluorocarbon producers.
   4. Government advice and other policy development: I do not provide advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engage in the development of significant policy positions of a government for a Montreal Protocol meeting.
   5. Paid research activities, fellowships or grants:- Except for my salary as an employee of Koura, I am not the recipient of any paid research activities or any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.
   6. Other interests: I do not have other interests related to the subject matter of the Technology and Economic Assessment Panel or the Montreal Protocol.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee and TEAP’s Task Force on Unexplained Emissions of CFC-11 is as part of my day to day Regulatory Manager role for Koura.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Peter Sleigh
Date: 28th April 2020

I, Jørgen Vestbo, nominated by Ministry of Environment and Food of Denmark, residing in Denmark, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Professor of Respiratory Medicine at the University of Manchester, Manchester, UK. My responsibilities include research and teaching in respiratory medicine and management of patients; my area of focus is on chronic obstructive pulmonary disease (COPD) and inhaled therapies. I also see respiratory outpatients in a clinic in Copenhagen, Denmark.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests , and those of my personal partner and dependents, include the following:
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: 
      I have received honoraria from pharmaceutical companies (AstraZeneca, Boehringer-Ingelheim, Chiesi, GSK and Novartis) for advising and presenting. All work is being invoiced through a Danish tax registered one-man company, Vestbo medical, VAT Reg No 21215430.
      My son, Jakob Vestbo, is a Key account manager of Chiesi in Denmark.
      My wife, Inge Vestbo, worked from 1985 to 2009 in the pharmaceutical industry in Denmark and the UK.
   4. Government advice and other policy development: 
      I am Chair of the Advocacy Council of the European Respiratory Society.
   5. Paid research activities, fellowships or grants: I have previously held grants from GSK and together with a junior researcher in my group (Alexander Mathioudakis) I hold a grant from Boehringer-Ingelheim UK (£70,000). 
   6. Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is personal (or from own NHS hospital endowment account).
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Jørgen Vestbo
Date: 28th April 2020
 

I, _Kristine Whorlow AM, nominated by _the Australian Government, residing in Melbourne, Australia, member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am the recently retired CEO of the National Asthma Council Australia. My responsibilities included producing the national treatment guidelines for asthma and implementing these through an extensive national program of primary care health professional education as well as conducting national promotional campaigns to promote community education. I was also responsible for conducting outreach education activities in Asia Pacific. I am currently the First Vice President of the Global Airways and Allergy Patient Platform (GAAPP), the only global patient organisation in this field whose main role is to support existing and emerging patient organisations dedicated to patient support and advocacy in airways disease and allergy.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests , and those of my late personal partner and dependents, include the following (if answer is yes, describe briefly)
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: my role as First Vice President of GAAPP does not conflict with that of MCTOC.
   4. Government advice and other policy development: none relevant.
   5. Paid research activities, fellowships or grants: none
   6. Other interests: none
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is myself.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Kristine Whorlow
Date: March 23, 2020
 

2021 DOI - Ashley Woodcock

I, Nee Sun CHOONG KWET YIVE, nominated by Government of Mauritius, residing in Mauritius, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am Associate Professor in Chemistry at the University of Mauritius. My responsibilities include teaching Physical and Analytical at undergraduate and post graduate levels and doing research in the field of environmental chemistry.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests¹, and those of my personal partner and dependents, include the following 
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). (add description of interest)
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: None
   4. Government advice and other policy development: I participated in national meetings organized by the Ministry of Environment, Mauritius to phase out ODSs.
   5. Paid research activities, fellowships or grants: None
   6. Other interests: None
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is Ozone Secretariat.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Nee Sun Choong Kwet Yive
Date: 29 April 2020

¹ When making a disclosure of interest, consider the COI Guidelines as a whole, and in particular the Annex which gives the following illustrative list of interests that should be disclosed –

1. A current proprietary interest of a member or his/her personal partner or dependent in a substance, technology or process (e.g., ownership of a patent) to be considered by the Technology and Economic Assessment Panel or any of its technical options committees or temporary subsidiary bodies;
2. A current financial interest of a member or his/her personal partner or dependent, e.g., shares or bonds in an entity with an interest in the subject matter of the meeting or work (but not shareholdings through general mutual funds or similar arrangements where the expert has no control over the selection of shares);
3. A current employment, consultancy, directorship or other position held by a Member or his/her personal partner or dependent, whether or not paid, in any entity which has an interest in the subject matter of the Technology and Economic Assessment Panel. This element of disclosure also includes paid consultancy efforts performed on behalf of an implementing agency to assist developing countries to adopt alternatives;
4. The provision of advice on significant issues to a government with respect to its implementation of the Montreal Protocol or engaging in the development of significant policy positions of a government for a Montreal Protocol meeting;
5. Performance of any paid research activities or receipt of any fellowships or grants for work related to a proposed use of an ozone-depleting substance or an alternative to a proposed use of an ozone depleting substance.

I, You Yizhong, nominated by China, residing in China, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am :1.Chief Editor of Journal of Aerosol Communication. 2.President of Aerosol Committee of China Packaging Federation. 3.Chief Pharmacist,Associate Chief Physician of The First People’s Hospital of Changzhou,China. My responsibilities include investigate aerosol and inhale drugs.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests[i], and those of my personal partner and dependents, include the following .
   • Proprietary interests: I do not have  proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces).
   • Financial interests: I do not have  ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work.
   • Employment, consultancy, directorship or other positions. No any intrest relevant to the MCTOC activity.
   • Government advice and other policy development: I have no any interests relevant to the MCTOC activity, including any provision of advice to government, organisations or institutions involved in policy development.
   • Paid research activities, fellowships or grants:no any ities, fellowships or grants relevant to the MCTOC activity
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is UNEP
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussion and decisions on topics related to the information that I have declined to disclose. 
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: You Yizhong

Date: April 15, 2020

I, ZHANG Lifei, nominated by China, residing in China, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Professor of National Research Center for Environmental Analysis and Measurement in China. My responsibilities include: Laboratory use and standard analytical method on carbon tetrachloride; Persistent organic pollutants unintentionally produced during tetrachloroethylene production; Chemical decomposition technologies on organic compounds and it’s mechanisms. 
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service. 
4. My interests, and those of my personal partner and dependents, include the following
   1. Proprietary interests: I do not have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). 
   2. Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   3. Employment, consultancy, directorship or other positions: None.
   4. Government advice and other policy development: None.
   5. Paid research activities, fellowships or grants: None.
   6. Other interests: None.
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is supported by UNEP.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I have not declined to disclose information falling within paragraph 10 of those Guidelines.  
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change. 
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: ZHANG Lifei
Date: 1st April 2020